Skip to main content

Table 2 Five-year outcomes of 5 different endpoints for all female patients with primary, non-metastatic, unilateral breast cancer treated at the Heidelberg Breast Care Unit between 01 January 2003 and 31 December 2012

From: Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study

 All patients (including in-situ) n = 4102 (including 499 in-situ cases)Patients with invasive cancer (excluding in-situ) n = 3603
LCR [%] (95 % CI)96.1 (95.3; 96.9)96.1 (95.3; 96.9)
DFS [%] (95 % CI)84.9 (83.6; 86.2)83.7 (82.2; 85.2)
DDFS [%] (95 % CI)86.9 (85.7; 88.1)85.7 (84.3; 87.1)
OS [%] (95 % CI)91.3 (90.2; 92.4)90.5 (89.3; 91.7)
ROS [%] (95 % CI)95.5 (94.3; 96.7)94.7 (93.4; 96.0)
  1. CI confidence interval, LCR local recurrence rate, DFS disease-free survival, DDFS distant disease-free survival, OS observed overall survival, ROS relative overall survival